“…Halvorsen et al ( 22 ) validated six microRNAs (miR-429, miR-205, miR-200b, miR-203, miR-125b, and miR-34b) that were candidate biomarkers for future screening detection, because their abundance in the serum of NSCLC patients was significantly higher than that in chronic obstructive pulmonary diseases (COPD) patients and healthy volunteers. The serum laminin levels measured by solid-phase sandwich enzyme-linked immunosorbent assay (ELISA) were significantly higher in NSCLC patients, and this method might be promising as a diagnostic supplement ( 23 ). The level of four serum markers (CEA, CYFRA21-1, NSE and miR-21) was measured in 50 NSCLC patients and 60 healthy donors, and the results indicated that serum miR-21 had the highest diagnostic value, whereas the combination of miR-21 and CYFRA21-1 improved the diagnostic efficiency for early NSCLC ( 24 ).…”